Rhizen Pharma Starts Dosing in Phase I/Ib Study of Novel PARP Inhibitor for Advanced Solid Tumors
Rhizen Pharmaceuticals has started dosing in a phase I/Ib trial to assess the efficiency of PARP inhibitor (RP12146) in advanced
Read more
DISEASES
Agilent’s PD-L1 IHC 22C3 pharmDx Assay Approved for TNBC use in EU
Agilent’s PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying Triple-Negative Breast Cancer (TNBC) patients for
Read more
First Evotec-BMS Academic BRIDGE Collaboration Projects to Focus on Oncology
The first two projects funded within the translational BRIDGE beLAB1407 collaboration will focus on new mechanisms to treat cancer, Evotec
Read more
FDA Panel in Favor of Pfizer’s COVID-19 Vaccine for Children Aged 5 to 12
The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted 17 to 0,
Read more
EC Approves Merck’s KEYTRUDA® for Triple-Negative Breast Cancer
KEYTRUDA® has been granted approval as a first-choice treatment in combination with chemotherapy for patients with locally recurrent unresectable or
Read more
Valneva’s COVID-19 Vaccine Candidate Shows Positive Results in Phase 3 Trial
French pharmaceutical company Valneva has reported positive results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001 in the Phase 3
Read more
FDA Expands Use of COVID-19 Vaccine Booster Dose in Eligible Populations
The US Food and Drug Administration has granted approval for administration of COVID-19 vaccine booster dosage, upgrading the emergency use
Read more
Genentech’s Investigational Antibody Wins BTD for Alzheimer’s Treatment
Genentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read more
Pan-Tumor IHC Screen Suggests FAP Target is Attractive for PTRT
A pan-tumor IHC screen identified high fibroblast activating protein (FAP) expression in multiple tumor types that correlated with in vitro
Read more
Tezepelumab gets ODD in the US for Eosinophilic Esophagitis
Tezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read more